We have located links that may give you full text access.
HIV-PASS (Pain and Sadness Support): Randomized controlled trial of a behavioral health intervention for interference due to pain in people living with HIV, chronic pain, and depression.
Psychosomatic Medicine 2023 Februrary 4
OBJECTIVE: To determine whether HIV-Pain and Sadness Support (HIV-PASS), a collaborative behavioral health intervention based on behavioral activation, is associated with decreased pain-related interference with daily activities, depression, and other outcomes in people living with HIV.
METHODS: We conducted a three-site clinical trial (n = 187) in which we randomly assigned participants to receive either HIV-PASS or health education (HE) control condition. In both conditions, participants received seven intervention sessions, comprised of an initial in-person joint meeting with the participant, their HIV primary care provider and a behavioral health specialist (BHS), and six, primarily telephone-based, meetings with the BHS and participant. The intervention period lasted three months and follow-up assessments were conducted for an additional nine months.
RESULTS: Compared to HE, HIV-PASS was associated with significantly lower pain-related interference with daily activities at the end of month 3 (our primary outcome; b = -1.31, 95% CI = -2.28, -0.34). We did not observe other differences between groups at three months in secondary outcomes that included worst or average pain in the past week, depression symptoms, anxiety, and perceived overall mental and physical health. There were no differences between groups on any outcomes at 12 months post-enrollment.
CONCLUSIONS: A targeted intervention can have positive effects on pain interference. At the end of intervention, effects we found were in a clinically significant range. However, effects diminished once the intervention period ended.Trial Registration: ClinicalTrials.gov NCT02766751.
METHODS: We conducted a three-site clinical trial (n = 187) in which we randomly assigned participants to receive either HIV-PASS or health education (HE) control condition. In both conditions, participants received seven intervention sessions, comprised of an initial in-person joint meeting with the participant, their HIV primary care provider and a behavioral health specialist (BHS), and six, primarily telephone-based, meetings with the BHS and participant. The intervention period lasted three months and follow-up assessments were conducted for an additional nine months.
RESULTS: Compared to HE, HIV-PASS was associated with significantly lower pain-related interference with daily activities at the end of month 3 (our primary outcome; b = -1.31, 95% CI = -2.28, -0.34). We did not observe other differences between groups at three months in secondary outcomes that included worst or average pain in the past week, depression symptoms, anxiety, and perceived overall mental and physical health. There were no differences between groups on any outcomes at 12 months post-enrollment.
CONCLUSIONS: A targeted intervention can have positive effects on pain interference. At the end of intervention, effects we found were in a clinically significant range. However, effects diminished once the intervention period ended.Trial Registration: ClinicalTrials.gov NCT02766751.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app